Aldosterone antagonism fails to attenuate age-associated left ventricular fibrosis

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 62, Issue 4, 2007, Pages 382-388

  Hyun, Seok Hwang ^a   Cirrincione, Georgina ^a   Thomas, D Paul ^b   McCormick, Richard J ^b   Boluyt, Marvin O ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF WYOMING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; COLLAGEN; MESSENGER RNA; MYOSIN HEAVY CHAIN BETA; SPIRONOLACTONE; VEGETABLE OIL; ALDOSTERONE ANTAGONIST; COLLAGEN TYPE 3; MYOSIN HEAVY CHAIN; VENTRICULAR MYOSIN;

ADOLESCENT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; FEMALE; FISCHER 344 RAT; HEART MUSCLE FIBROSIS; HYPERTENSION; IMMUNOBLOTTING; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT; AGING; ANIMAL; BLOOD; DRUG ANTAGONISM; FIBROSIS; GENE EXPRESSION; GENETICS; HEART MUSCLE; HEART VENTRICLE; METABOLISM; PATHOLOGY; TISSUE DISTRIBUTION;

RATTUS;

AGING; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; ATRIAL NATRIURETIC FACTOR; COLLAGEN; COLLAGEN TYPE III; FEMALE; FIBROSIS; GENE EXPRESSION; HEART VENTRICLES; MYOCARDIUM; MYOSIN HEAVY CHAINS; RATS; RATS, INBRED F344; RNA, MESSENGER; SPIRONOLACTONE; TISSUE DISTRIBUTION; VENTRICULAR MYOSINS;

EID: 34250375256     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/62.4.382     Document Type: Article

References (51)

1. Ahmed A. American College of Cardiology/American Heart Association chronic heart failure evaluation and management guidelines: relevance to the geriatric practice. J Am Geriatr Soc. 2003;51:123-126.
2. Huysman JAN, Vliegen HW, VanderLaarse A, Eulderinnk F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract. 1989;184:577-581.
3. Pearlman ES, Weber KT, Janicki JS, Pietra G, Fishman AP. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982;46:158-164.
4. Beltrami CA, Finato N, Rocco M, et al. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol. 1995;27:291-305.
5. Marino TA, Kent RL, Uboh CE, Fernandez E, Thompson EW, Cooper G 4th Structural analysis of pressure versus volume overload hypertrophy of cat right ventricle. Am J Physiol. 1985;249:H371-H379.
6. Annoni G, Luvara G, Arosio B, et al. Age-dependent expression of fibrosis-related genes and collagen deposition in the rat myocardium. Mech Ageing Dev. 1998;101:57-72.
7. Besse S, Robert V, Assayag P, Delcayre C, Swynghedauw B. Nonsynchronous changes in myocardial collagen mRNA and protein during aging. Effect of DOCA-salt hypertension. Am J Physiol. 1994;267:H2237-H2244.
8. Boluyt MO, Lakatta EG. Cardiovascular aging in health. In: Bittar EE, Altschuld RA, Haworth RA, eds. Advances in Organ Biology: Heart Metabolism in Failure. Vol. 4B. Stamford, CT: JAI Press; 1998.
9. Thomas DP, McCormick RJ, Zimmerman SD, Vadlamudi RK, Gosselin LE. Aging- and training-induced alterations in collagen characteristics of rat left ventricle and papillary muscle. Am J Physiol. 1992;263: H778-H783.
10. Thomas DP, Zimmerman SD, Hansen TR, Martin DT, McCormick RJ. Collagen gene expression in rat left ventricle: interactive effect of age and exercise training. J Appl Physiol. 2000;89:1462-1468.
11. Vanpee D, Swine CH. Elderly heart failure patients with drug-induced serious hyperkalemia. Aging (Milan). 2000;12:315-319.
12. Yao J, Eghbali M. Decreased collagen gene expression and absence of fibrosis in thyroid hormone-induced myocardial hypertrophy. Response of cardiac fibroblasts to thyroid hormone in vitro. Circ Res. 1992;71:831-839.
13. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565-1574.
14. Boluyt MO, Opiteck JA, Devor ST, White TP. Age effects on the adaptive response of the female rat heart following aortic constriction. J Gerontol Biol Sci. 2000;55A:B307-B314.
15. Spurgeon H, Thorne P, Yin F, Shock N, Weisfeldt M. Increased dynamic stiffness of trabeculae carneae from senescent rats. Am J Physiol. 1977;232:H373-H380.
16. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
17. Boluyt MO, Bing OH. The lonely failing heart: a case for ECM genes. Cardiovasc Res. 1995;30:836-840.
18. Medugorac I. Collagen type distribution in the mammalian left ventricle during growth and aging. Res Exp Med. 1982;180:255-262.
19. Mukherjee D, Sen S. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res. 1990;67:1474-1480.
20. Yang CM, Kandaswamy V, Young D, Sen S. Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc Res. 1997;36:236-245.
21. Lorell BH. Transition from hypertrophy to failure. Circulation. 1997; 96:3824-3827.
22. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
23. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The randomized aldactone evaluation study [RALES]). Am J Cardiol. 1996;78:902-907.
24. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77.
25. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700-2706.
26. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32:865-879.
27. Rocha R, Stier T. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308-314.
28. Brilla CG, Zhou G, Matsubara LS, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820.
29. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-575.
30. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A-16A.
31. Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ M. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ace inhibition. Circulation. 2000;102:2325-2328.
32. Delyani J, Robinson E, Rudolph A. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol. 2001;50:H647-H654.
33. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
34. Bouvy ML, Heerdink ER, Herings RM. Long-term therapy with spironolactone. Pharm World Sci. 2001;23:132-134.
35. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
36. Thomas DP, Cotter TA, Li X, McCormick RJ, Gosselin LE. Exercise training attenuates aging-associated increases in collagen and collagen crosslinking of the left but not the right ventricle in the rat. Eur J Appl Physiol. 2001;85:164-169.
37. Boluyt MO, Opiteck JA, Esser KA, White TP. Cardiac adaptations to aortic constriction in adult and aged rats. Am J Physiol. 1989;257:H643-H648.
38. Boluyt MO, Devor ST, Opiteck JA, White TP. Age-associated changes in the regional variation of cardiac myosin isoforms of female rats. J Gerontol Biol Sci. 1999;54:B313-B317.
39. Boluyt MO, Converso K, Hwang HS, Mikkor A, Russell MW. Echocardiographic assessment of age-associated changes in systolic and diastolic function of the female F344 rat heart. J Appl Physiol. 2004;96:822-828.
40. Boluyt MO, Li ZB, Loyd AM, Scalia AF, Cirrincione GM, Jackson RR. The mTOR/p70S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo. Cardiovasc Drugs Ther. 2004;18,257-267.
41. Boluyt MO, O'Neill L, Meredith AL, et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix proteins. Circ Res. 1994;75:23-32.
42. Cirrincione GM, Boluyt MO, Hwang HS, Bleske BE. 3-Hydroxy-3-methyl- glutaryl coenzyme A reductase inhibition and extracellular matrix gene expression in the pressure-overloaded rat heart. J Cardiovasc Pharmacol 2006;47:521-530.
43. Curran-Everett D, Benos DJ. Guidelines for reporting statistics in journals published by the American Physiological Society. Am J Physiol. 2004;287:R247-R249.
44. Younes A, Boluyt MO, O'Neill L, Meredith AL, Crow MT, Lakatta EG. Age-associated increase in rat ventricular ANP gene expression correlates with cardiac hypertrophy. Am J Physiol. 1995;269:H1003-H1008.
45. McCormick RJ, Thomas DP. Collagen crosslinking in the heart: relationship to development and function. Basic Appl Myol. 1998;8:143-150.
46. Nagata K, Obata K, Xu J, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656-664.
47. Yamamuro M, Yoshimura M, Nakayama M, et al. Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology. 2006;147:1314-1321.
48. Okoshi MP, Yan X, Okoshi K, et al. Aldosterone directly stimulates cardiac myocyte hypertrophy. J Card Fail. 2004;10:511-518.
49. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 1997;17:1152-1156.
50. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol. 2001;37:662-667.
51. Thom T, Haase N, Rosamond W, et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics: 2006 Update: A Report From the American Heart Association Statistics Committee and Stoke Statistics Subcommittee. Circulation. 2006;113(6):e85-151.